Who are Amidate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tuazole, Alfadione, Byfavo, Muscoril, SEVOFLURANE, Suprane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amidate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Amidate — Competitive Intelligence Brief

Amidate (Etomidate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: General Anesthetic [EPC]. Area: Metabolic.

marketed General Anesthetic [EPC] GABA A receptor alpha-2/beta-2/gamma-2 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Amidate (Etomidate) — Pfizer Inc..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amidate TARGET	Etomidate	Pfizer Inc.	marketed	General Anesthetic [EPC]	GABA A receptor alpha-2/beta-2/gamma-2
Tuazole	METHAQUALONE		marketed	methaqualone	GABA-A receptor alpha-6/beta-2, GABA A receptor alpha-2/beta-2/gamma-2, GABA A receptor alpha-3/beta-2/gamma-2
Alfadione	ALFAXALONE		marketed	alfaxalone	Sodium- and chloride-dependent GABA transporter 1, GABA A receptor alpha-2/beta-2/gamma-2, GABA-A receptor alpha-1/beta-2/gamma-2
Byfavo	Byfavo	Chungbuk National University Hospital	marketed		GABA A receptor alpha-2/beta-2/gamma-2, GABA A receptor alpha-3/beta-2/gamma-2, GABA A receptor alpha-5/beta-2/gamma-2
Muscoril	THIOCOLCHICOSIDE		phase 3		GABA A receptor alpha-1/beta-1/gamma-2, GABA A receptor alpha-2/beta-2/gamma-2, GABA-A receptor alpha-1/beta-2/gamma-2
SEVOFLURANE	SEVOFLURANE		marketed	General Anesthetic [EPC]		1995-01-01
Suprane	DESFLURANE	Baxter	marketed	General Anesthetic [EPC]	GABA-A receptor; anion channel	1992-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (General Anesthetic [EPC] class)

· 2 drugs in this class
Baxter · 2 drugs in this class
Pfizer · 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amidate — Competitive Intelligence Brief. https://druglandscape.com/ci/amidate. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab